KRAS and cancer: One of these new approaches is based on synthetic lethality to target cancer cells with mutant KRAS. The development of screenings, mostly based on CRISPR/Cas9 technology or small interfering RNAs (siRNAs), to identify targets of synthetic lethality has been growing in recent years [160].